Latest News and Press Releases

  UPPSALA, SWEDEN – årsstämman i LIDDS AB (publ) hölls den 17 maj, 2021   Årsstämman fastställde i årsredovisningen intagen resultaträkning och balansräkning samt...

  UPPSALA, SWEDEN – LIDDS Annual General Meeting (AGM) was held on May 17, 2021.   The AGM adopted the income statement and balance sheet and the consolidated income statement...

JANUARY – MARCH 2021 Net sales amounted to MSEK 0.6 (0.0)Operating expenses amounted to MSEK -11.4 (-8.0)Profit/loss before and after tax amounted to MSEK -10.8 (-8.0)Earnings per share amounted to...

UPPSALA, SWEDEN – LIDDS publishes Annual Report for 2020 The Annual Report is attached to this press release and alos available on LIDDS website: https://liddspharma.com/investors/#financial-reports....

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of...

UPPSALA, SWEDEN - Aktieägarna i LIDDS AB (publ), org.nr. 556580-2856, kallas till årsstämma i bolagets lokaler på Uppsala Business Park med besöksadress Rapsgatan 7 i Uppsala måndagen den 17 maj 2021...

UPPSALA, SWEDEN – The shareholders of LIDDS AB (publ), corp. ID no. 556580-2856, are invited to the Annual General Meeting in the company's premises at Uppsala Business Park with visiting address...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the journal International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been...

Finwire TV has done an interview in Swedish with LIDDS CEO, Monica Wallter, about her tenure as CEO of LIDDS, the recent company news and upcoming milestones. The interview is found here:...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today an update on the clinical program for the prostate cancer drug candidate Liproca® Depot. Based on the interactions that LIDDS’ licensee for China,...